Supported by

Catalogue of collaboration profiles

back to list
Company

University of Aberdeen Research and Innovation

Street
King's College
ZIP Code
AB24 3FX
City
Aberdeen
Country
United Kingdom


Company Profile:
The University of Aberdeen is among the UK’s top research universities, with key areas of excellence within life sciences, molecular imaging and biomedical research. Internationally competitve research programmes in key research themes address biological problems and disease areas of major clinical importance.

R&I is the first point of contact for business, facilitating access to the University's researchers, services, and technologies, and offering a range of commercial opportunities arising from our research activities. It welcomes contact from all companies interested in accessing our researchers and facilities, collaborative research programmes, licensing of university technology, or wishing to learn more about short courses and continuing professional development.
Profiltitel

Novel Antimicrobial Peptide

What we offer:
The need for new antimicrobial agents is greater than ever because of the continuing appearance of drug resistance in common pathogens and the emergence of new pathogens. We have discovered such a novel antimicrobial peptide from an arthropod source. The peptide is produced physiologically as a GPI-anchored peptide, however its activity as a soluble recombinant protein has been demonstrated. The novel agent shows broad spectrum and bactericidal activity against both gram negative and gram positive bacteria, including clinical isolates. The novel antimicrobial peptide appears to have a mechanism of action distinct from pore formation since it enters and accumulates inside bacteria, and binds DNA in vitro. The novel peptide is not cytotoxic against mammalian cells.

What are we looking for:
We are looking for a company to in-license or partner the technology to complete development.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

Rapid Screening Test for Glaucoma

What we offer:
Worldwide glaucoma is a leading cause of irreversible adult blindness. There is no cure for glaucoma but early diagnosis can allow disease progression to be stopped. Current readily-available optometry tests have a high false positive rate and do not reliably detect early-stage disease. A new rapid and non-invasive test has been developed for detecting early stage glaucoma by researchers at the University of Aberdeen. The test is PC-based and uses the way that humans perceive moving objects to detect abnormalities in visual processing associated with retinal neuropathies such as glaucoma. Performance on the test relates to the degree of neural damage to the retina.

What are we looking for:
We are looking for a company to in-license or partner the technology to complete development.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

Molecular delivery tool for biomedical research

What we offer:
We have developed a novel method for straightforward synthesis of a natural pore-forming agent (poly-APS) that forms transient (reversible) pores in the membrane of a wide variety of cell types, thus allowing access of small molecules and macromolecules to cells. The new method provides for synthesis of low-dispersity poly-APS with different pore sizes and variable linking chains which could be used to tune the biological properties for specific applications. These poly-APS molecules are highly applicable to delivery of molecules in biomedical research due to their high stability and water solubility and have been shown to deliver small molecules, DNA and peptides to cells. Two new chemical entities have been prepared which show greater potency than naturally-isolated poly-APS.

What are we looking for:
We are looking for a company to in-license or partner the technology to complete development.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

Method to improve DCE MRI

What we offer:
Researchers at the University of Aberdeen have developed an improved method of undertaking DCE MRI scans. The method can be easily applied in the clinical setting and is not dependent on a particular scanner type or manufacturer. It is anticipated the method will allow standardisation of measurements from different subjects across different scanners

What are we looking for:
We are looking for a company to in-license the technology to complete development.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

A Predictive Biomaker and Novel Drug Target for Lung Cancer

What we offer:
Analysis of the Non Small Cell Lung Cancer (NSCLC) transcriptome revealed a number of biomarkers whose expression profile when monitored in patients predicts response to chemotherapy with platinum based drugs. Resistance to these drugs is a major problem with only 30-40% responding to treatment. The development of a diagnostic test for these markers will enable individual patient treatment plans to be drawn up to best tackle NSCLC. One of the biomarkers discovered is Serpin B3. This lysosomal protease inhibitor is a negative regulator of programmed cell death. Exciting data from the Aberdeen team suggests that expression of Serpin B 3 prevents cancer cell death through the lysosomal mediated alternative cell death pathway. This makes it an attractive therapeutic target.

What are we looking for:
The University is keen to develop this technology and is actively seeking parties interested in licensing and co-development.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

General 18F labelling method for fragment antibodies and biotin

What we offer:
Currently, labelling of macromolecules with 18-F involves preparation of a prosthetic group using a time-consuming multistep procedure in which the short-lived 18-F nuclide is incorporated early. We are developing dendrimers and nanoparticles with multiple fluorinatable groups which can be conjugated to targeting molecules such as antibody fragments for direct 18-F labelling or to biotin for imaging of cell surface molecules pre-labelled with avidin. Fluorination conditions are mild (room temperature, aqueous solutions) and produce high labelling efficiency thus eliminating the need for a purification step. These factors mean that ready-assembled tracers can be fluorinated in a short time period with the potential of a one-pot synthesis and without a requirement for specialised PET rigs.

What are we looking for:
We are looking for a company to in-license or partner the technology to complete development.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

Kosterlitz Centre for Therapeutics

What we offer:
The Kosterlitz Centre for Therapeutics is a new initiative that seeks to capitalise on the wealth of research expertise and world-class research programmes in the University of Aberdeen. Biological discoveries that emanate from this research will be translated into commercially- and medically-valuable therapeutics via Centre.

The mission of the Kosterlitz Centre for Therapeutics is to facilitate the translation of biological innovation into new ways of treating, diagnosing and understanding diseases.

What are we looking for:
The Kosterlitz Centre for Therapeutics has a number of projects in development (http://www.abdn.ac.uk/kosterlitz/projects/). The University is seeking companies interested in partnering applications for funding for research development.

Collaboration sought:
  • Research & Development
  • Technical Co-operation


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

Gene associated with schizophrenia

What we offer:
Researchers at the University of Aberdeen have identified a novel kinase that appears to interact with DISC1 and is implicated in schizophrenia. The DISC1 gene is one of the strongest susceptibility factors for schizophrenia and is the subject of intensive research. The novel kinase gene was identified from a study of schizophrenic patients. This kinase interacts with DISC1 raising the possibility that it might be involved in the regulation of DISC1. Hence mutations in the kinase have the potential to be markers for schizophrenia.

What are we looking for:
We are looking for a company to in-license or partner the technology to complete development.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

Novel oomycete protein translocation mechanism as pesticide target or drug delivery mechanism

What we offer:
We have discovered a novel method of protein translocation in oomyctes. This is a natural target for novel pesticides and development of disease resistant plants and there is potential to develop novel drug delivery system for eukaryotes as the translocation mechanism utilises ubiquitous cell surface features.

RXLR effector proteins have been discovered to enter host cells, not through the RXLR motif as previously suspected, but rather through interaction between an additional effector domain and undisclosed features on the surface of the host cell. These features are common to eukaryotic cells. Additionally we have elucidated that RXLR motif enables dimerisation of effector proteins to occur which increases the translocation efficiency by promoting binding to the cell surface.

What are we looking for:
The University is keen to work with industry to develop this technology.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
Profiltitel

A new technique to recover latent fingerprints

What we offer:
Despite the capabilities of suitable non-toxic organic reagents there are still not many to choose from that are regularly used. The Home Office highlighted fingerprinting as an existing technology insufficient to meet the needs of the service. There is a need to find improved reagents that will develop fingerprints at the scene of crimes.

We have developed a new non-toxic, stable and easy to use developing reagent.
The reagent has been tested on paper. The fingerprint developed above was placed on paper from a dry finger; i.e no additional layers of known print enhancers were applied such as sweat or oils from the skin. The formulation and concentration was typical for DFO. It performs well in depletion and split depletion runs compared to DFO.

What are we looking for:
The University is seeking an industrial partner for development of this technology.

Collaboration sought:
  • Research & Development
  • Licence


Responsible

Ann Lewendon

Commercialisation Coordinator
back to list

Participants

Enterprise Europe ScotlandAboleo LtdAccuro BiologicsAlliance BootsBeta TechnologyBitWiseFW Medical LLPInnova Partnerships LtdInterface-The knowledge connection for businessMarks and Clerk LLPMcClure Naismith LLPThe Medical Device Company LtdQuantics Consulting LtdScottish Health InnovationsPharmalinksSistemic LtdStrathclyde Institute of Medical DevicesSynthetic Nanomachines LtdTissue SolutionsUniversity of AberdeenEllis IP LtdPharmacells LtdCeltic CatalystsPharmaceutical eConsultingWeatherologyControlled TherapeuticsSphere Fluidics LimitedHighland Clinical Research FacilityMoorfields PharmaceuticalsEdinburgh Science Trianglebeocarta LtdRostiShore DesignPomBioTech GmbHIMG Innovations-Management  GmbH/ Enterprise Europe NetworkThe Eurotactics ConsultancyIBA GmbHSGS Life Science ServicesOnorach  ClinicalWideblueEnterprise Europe YorkshireAptuit ConsultingMosaigen/Endeavour CapitalEscubed LtdEulysis Ltd.Raumedic LtdCatalent Pharma SolutionsEscubed LtdUniversity of Aberdeen Research and InnovationSPRI - Basque Enterprise Europe NetworkLicentia LtdTake The WindRoslin CellabMoredun ScientificEnterprise Europe East of EnglandAvantiCell ScienceXeroshield Ltd.ImmunoSolv LimitedLeoben Research LimitedPRAXI / HELP-FORWARD Network &The Hellenic BioClusterEMBIO Diagnostics Ltd


© 2010 ConVerve GmbH | all rights reserved